ea0089t4 | Trials In Progress | NANETS2022
W. McGarrah Patrick
, Naik Shruthi
, R. Halfdanarson Thorvardur
, Leventakos Konstantinos
, Whye Peng Kah
, J. Russell Stephen
, A. Adjei Alex
, R. Molina Julian
Background: Poorly differentiated neuroendocrine carcinoma (NEC) is an aggressive malignancy comprising both pulmonary and extrapulmonary primary sites. NEC includes both small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), as well as other neuroendocrine carcinomas arising from any primary organ. The optimal systemic therapy beyond first line platinum and etoposide is not established. There is a critical need to improve upon the median survival in th...